Nocion Therapeutics
Watertown, US · Founded 2017 · Delaware corporation · 19 employees on LinkedIn · 6 known investors
Find your way into Nocion Therapeutics
1,477 people in our graph share verified history with the Nocion Therapeutics team — schools, employers, funds. One of them is your warm intro.
Wesley Chanunlockedknows Mark Rosenblum · together at Massachusetts Institute of Technology (overlapped)
×7knows the team · via Massachusetts Institute of Technology
×2knows the team · via Cornell
×2knows the team · via Brandeis University
Nocion Therapeutics develops small molecule charged sodium channel blockers (nocions) designed to silence overactive sensory nerves. The company is advancing taplucainium inhalation powder, a first-in-class therapy in Phase 2b clinical development for refractory and unexplained chronic cough, with potential applications in pain, itch, and other conditions driven by neurogenic inflammation.
Founders & leadership
MF
MATTHEW FRANKELinChief Medical OfficerHe brings over two decades of clinical development and medical affairs experience across major biopharmaceutical companies including Novartis (where he led the Immunology and Dermatology Medical Unit), Boehringer Ingelheim (Vice President of Clinical Development overseeing oncology, immunology, pulmonary, and CNS programs), and Chemomab (Chief Medical Officer). He holds an M.D. from UCLA, an MBA from Northwestern University's Kellogg School of Management, and a B.A. from Vassar College, and is board-certified in internal medicine.
PC
PETER COUROSSIExecutive
RB
RICHARD BATYCKYExecutive
JE
JAMES ELLISExecutive
ML
MICHAEL LIPPinSenior Vice President, Pharmaceutical Development2019–2023Michael Lipp holds a B.S. in Chemical Engineering from Cornell University and a Ph.D. in Chemical Engineering and Materials Science from UC Santa Barbara, with over two decades of experience in pharmaceutical development and drug delivery across preclinical through commercial stages. He previously held senior roles in pharmaceutical development at Nocion Therapeutics, Civitas Therapeutics (acquired by Acorda), Pulmatrix, and Alkermes, and began his career as a postdoctoral fellow and staff scientist at Advanced Inhalation Research focusing on pulmonary product development.
CS
CHRISTOPHER SILBERinChief Medical Officer2020–2023
BM
BRIDGET M. COLEinSenior Vice President & Head of Chemistry2020–2023Bridget M. Cole is an Executive Officer at Nocion Therapeutics with a background in medicinal chemistry and drug discovery; she has directed discovery research and managed chemistry, manufacturing, controls, and preclinical development activities across multiple compounds from screening through Phase 2 clinical development.
Board
VM
VIJAY MURTHYBoard director
PO
PINI ORBACHBoard director
RH
ROSY HUBoard director
FD
Investors · 6
Canaan Partners✓ verifiedStamford · $500K – $20Mvia Julie Grant · board
F-Prime CapitalCambridge · $3M – $10M
Mission BiocapitalSan Francisco · $500K
Monograph Capital PartnersLondonvia Freddie Dear · board
OUP (Osage University Partners)Bala Cynwyd · $1M – $20M
Osage University PartnersreportedBala Cynwyd
Reported raises · per SEC filings
Form D private placements$76.1M disclosed across 4 rounds · 2021–2025
▶$23MraisedMar 2026 · 13 investors · PharmaceuticalsRule 506(b)
▶$23MraisedMar 2026 · 13 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- VIJAY MURTHYDirector
- JULIE GRANTDirector
- PINI ORBACHDirector
- ROSY HUDirector
- MATTHEW FRANKELExecutive Officer
- PETER COUROSSIExecutive Officer
- RICHARD BATYCKYExecutive Officer, Director
- JAMES ELLISExecutive Officer
- FREDDIE DEARDirector
- MICHAEL HIGGINSDirector
- Offering amount
- $23M
- Amount sold
- $23M
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$31.1MraisedMar 2024 · 13 investors · PharmaceuticalsRule 506(b)
▶$31.1MraisedMar 2024 · 13 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- JULIE GRANTDirector
- ROSY HUDirector
- BERNARD SILVERMANExecutive Officer
- RICHARD BATYCKYExecutive Officer, Director
- FREDDIE DEARDirector
- PINI ORBACHDirector
- PETER COUROSSIExecutive Officer
- MICHAEL HIGGINSDirector
- JAMES ELLISExecutive Officer
- VIJAY MURTHYDirector
- Offering amount
- $70M
- Amount sold
- $31.1M
- First sale
- Feb 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7MraisedAug 2022 · 10 investors · PharmaceuticalsRule 506(b)
▶$7MraisedAug 2022 · 10 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- JULIE PAPANEK GRANTDirector
- BRIDGET M. COLEExecutive Officer
- JESSICA ALSTONDirector
- MICHAEL HIGGINSDirector
- RICHARD BATYCKYExecutive Officer, Director
- MICHAEL LIPPExecutive Officer
- JONATHAN GARENExecutive Officer
- MEREDITH FISHERDirector
- JAMES ELLISExecutive Officer
- CHRISTOPHER SILBERExecutive Officer
- Offering amount
- $17M
- Amount sold
- $7M
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15MraisedJan 2021 · 11 investors · PharmaceuticalsRule 506(b)
▶$15MraisedJan 2021 · 11 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- MICHAEL HIGGINSDirector
- JULIE PAPANEK GRANTDirector
- MEREDITH FISHERDirector
- JESSICA ALSTONDirector
- MICHAEL LIPPExecutive Officer
- JAMES ELLISExecutive Officer
- CHRISTOPHER SILBERExecutive Officer
- RICHARD BATYCKYExecutive Officer, Director
- BRIDGET M. COLEExecutive Officer
- Offering amount
- $25M
- Amount sold
- $15M
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Maxion Therapeutics Website15 shared keywordsMaxion Therapeutics develops protein and antibody therapeutics using its patented KnotBody technology, which fuses cysteine-rich miniproteins (Knottins) into antibody binding loops to target ion channels and GPCRs. It focuses on first-in-class and best-in-class treatments for diseases driven by ion channel and GPCR dysfunction, including pain, autoimmune and cardiovascular conditions.
Alexion Pharmaceuticals14 shared keywordsAlexion is a biopharmaceutical company focused on research and development of treatments for rare diseases, serving rare disease patients and their families worldwide.
Vividion Therapeutics13 shared keywordsVividion Therapeutics develops small molecule therapeutics using a covalent-first chemoproteomics approach to identify and target previously undruggable proteins. The company operates across the full drug development spectrum from discovery to clinical development.
Companies competing with Nocion Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Nocion Therapeutics do?
- Nocion Therapeutics develops small molecule charged sodium channel blockers (nocions) designed to silence overactive sensory nerves. The company is advancing taplucainium inhalation powder, a first-in-class therapy in Phase 2b clinical development for refractory and unexplained chronic cough, with potential applications in pain, itch, and other conditions driven by neurogenic inflammation.
- Who are Nocion Therapeutics's investors?
- Nocion Therapeutics's investors include Canaan Partners, F-Prime Capital, Mission Biocapital, Monograph Capital Partners, OUP (Osage University Partners), Osage University Partners.
- How much funding has Nocion Therapeutics raised?
- Nocion Therapeutics has disclosed $76.1M raised across 4 rounds.
- Where is Nocion Therapeutics headquartered?
- Nocion Therapeutics is headquartered in Watertown, US.